ArticleFrontiers in oncology2019

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines.

Gro Elise Rødland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.